In this section
Assorted resources on conditions connected to Cardiology.
Latest information on diseases in Dermatology.
A detailed look at conditions connected to Endocrinology.
Gastroenterology and Hepatology
In-depth material on Gastroenterology and Hepatology.
Assorted resources on conditions connected to Haematology.
Immunology, the immune system and immune-mediated diseases.
A detailed look at conditions connected to Infectious Diseases.
Assorted resources on conditions related to Nephrology.
Neurology (CNS) and Pain
Learning materials and guidelines on Neurology (CNS) and Pain.
A detailed look at conditions connected to Oncology.
Assorted resources on conditions connected to Ophthalmology.
In-depth material on Respiratory conditions.
Latest information on diseases in Rheumatology.
Learning materials and guidelines on Urology.
Seagen Inc and Genmab A/S announced that the FDA has granted accelerated approval to Tivdak (tisotumab vedotin-tftv), the first and only approved antibody-drug conjugate (ADC) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Mirati Therapeutics, Inc.,announced results from a cohort of the Phase 1/II KRYSTAL–1 study evaluating adagrasib at the 600mg BID dose as both monotherapy and in combination with cetuximab in patients with heavily pretreated colorectal cancer harboring a KRASG12C mutation.
AbbVie has submitted an application to the FDA seeking approval for Skyrizi (risankizumab-rzaa) (600 mg intravenous (IV) induction and 360 mg subcutaneous (SC) maintenance therapy), an interleukin-23 (IL-23) inhibitor, for the treatment of patients 16 years and older with moderate to severe Crohn's disease.
You may be interested in...
Intralesional photodynamic therapy in hidradenitis suppurativa: Getting closer to the target
The successful treatment of hidradenitis suppurativa (HS) with intralesional photodynamic therapy (IL-PDT) has been previously reported in some case series published a few years ago. We present additional data and patient outcome for this form of PDT.
Serum high-sensitivity C-reactive protein, tumor necrosis factor-α, interleukin (IL)-1β, IL-17A and IL-23 levels in patients with hidradenitis suppurativa
Objectives: To assess the serum levels of proinflammatory cytokines TNF-α, IL-1β, IL-17A, IL-23 and high-sensitivity C-reactive protein (hs-CRP) in patients with HS and to evaluate the impact of treatment on cytokine levels.